Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 26;104(39):e44743.
doi: 10.1097/MD.0000000000044743.

The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer

Tarkan Yetişyiğit  1 , Kubilay Karaboyun  2 , Yakup İriağaç  3 , Eyyüp Çavdar  4 , Meltem Öznur  5 , Erdoğan Selçuk Şeber  4 , Burhan Turgut  6
Affiliations
Free article

The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer

Tarkan Yetişyiğit et al. Medicine (Baltimore). .
Free article

Abstract

Background: The prognostic and predictive role of the interaction of the immune system with the tumor during the disease process has become increasingly important in recent years. T lymphocyte subgroups in peripheral blood can be used to monitor this dynamic interaction. We evaluated the relationship between baseline peripheral T lymphocyte subsets and treatment response (best objective response) in 47 breast cancer patients receiving neoadjuvant chemotherapy.

Methods: This study investigated the impact of initial peripheral T lymphocyte subsets on neoadjuvant chemotherapy response in patients with invasive ductal breast. A total of 47 consecutive patients whose peripheral blood samples were able was included in the study group. The patients' T lymphocyte subsets were measured before treatment. The patients were then followed up to assess their treatment response.

Results: In our study, we found a significant negative relationship between baseline CD3, CD4, and CD8 absolute counts and pathologic complete response. We also found that high CD4/programmed cell death protein 1 expression (OR: 0.212, 95% CI: 0.061-0.735, P = .015) and high CD8/programmed cell death protein 1 expression (OR: 0.250, 95% CI: 0.073-0.858, P = .028) from baseline peripheral T lymphocyte were correlated with poor pathologic complete response.

Conclusions: These results suggest that T lymphocyte subsets may be a predictive biomarker for treatment response in patients with breast cancer undergoing neoadjuvant chemotherapy. Further studies are needed to confirm these findings and to identify the optimal T lymphocyte subset for predicting treatment response.

Keywords: T lymphocytes; absolute CD4+ lymphocytes; absolute CD8+ lymphocytes; breast cancer; neoadjuvant therapy.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Seer cancer stat facts: Female breast cancer. National Cancer Institute, 2023. https://seer.cancer.gov/statfacts/html/breast.html. Accessed October 11, 2023.
    1. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.
    1. Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study. Ann Surg Oncol. 2016;23:3467–74.
    1. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814–9.
    1. Lv Y, Li Y, Mu W, Fu H. Factors affecting pathological complete response after neoadjuvant chemotherapy in operable primary breast cancer. J Coll Physicians Surg Pak. 2020;30:389–93.

MeSH terms

Substances